The Royal Melbourne Hospital
Welcome,         Profile    Billing    Logout  
 28 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Colman, Peter C
FAME 1 EYE, NCT01320345 / ACTRN12611000249954: The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Recruiting
3
450
Europe, RoW
Fenofibrate, Inert lactose placebo
University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc
Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
12/24
12/25
Kwan, Patrick
NCT05219617 / 2022-001256-42: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Recruiting
3
252
Europe, US, RoW
Carisbamate
SK Life Science, Inc., SK Life Science, Inc
Seizures, Lennox Gastaut Syndrome
06/25
06/26
Anderson, Paul
ZEST EU, NCT03577236: The Zenflow Spring System EU Safety and Performance Study

Recruiting
N/A
50
RoW
Zenflow Spring System, Spring Implant
Zenflow, Inc.
Benign Prostatic Hyperplasia
12/22
05/24
VAPEUR RCT, NCT04838769: REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

Active, not recruiting
N/A
154
Europe, RoW
REZŪM, alpha blocker and 5-alpha reductase inhibitor, Dual Drug Therapy
Boston Scientific Corporation
Benign Prostatic Hyperplasia (BPH)
02/26
03/27
Szer, Jeff
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients

Recruiting
1/2
50
Europe, RoW
ADX-038, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Paroxysmal Nocturnal Hemoglobinuria (PNH)
03/26
09/26
Slavin, Monica
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Royse, Alistair
SURE-AVR, NCT02679404: Sorin Universal REgistry on Aortic Valve Replacement

Terminated
N/A
2758
Europe, Canada, US, RoW
Corcym S.r.l
Aortic Valve Disease, Aortic Stenosis
03/21
03/21
Mann, Bruce
AUS-PREDICT, NCT04916808: The Registry for DCIS Patients With DCISionRT Testing

Recruiting
N/A
1500
RoW
DCISionRT Test
PreludeDx
DCIS
05/24
05/34
Sood, Siddharth
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
Steinfort, Daniel
NCT06158971: Feasibility Study of the Microwave Ablation System for Lung Tissue Ablation

Recruiting
N/A
10
RoW
Flexible Bronchoscopic Microwave Ablation
phenoMapper, LLC, NIH/NCI - Grant award number: R01CA218357
Lung Neoplasm
01/25
01/25
BREATHE-1, NCT05854550: First in Human Study to Assess an Implant to Treat Severe Emphysema

Active, not recruiting
N/A
48
RoW
Apreo Implant Group
Apreo Health, Inc.
Emphysema or COPD
10/24
04/25
Thomas, Ben
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05307822: CSD210903: A Study to Determine Subject Puffing Patterns of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Ambulatory Setting

Completed
N/A
194
US
Non-combusted cigarette variant 42001401, Non-combusted cigarette variant 42001399, Non-combusted cigarette variant 40007386, Non-combusted cigarette variant 42001402
RAI Services Company
Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
11/22
11/22
Hughes, Peter
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Terminated
3
194
Europe, Canada, US, RoW
Clazakizumab, Physiologic saline solution
CSL Behring, ICON Clinical Research
Antibody-mediated Rejection
04/24
04/24
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
Barbour, Thomas D
No trials found
Holt, Steve
No trials found
Perucca, Piero
No trials found
Furrer, Marc A
No trials found
Williams, Zelda
No trials found
Baker, Rob
No trials found

Download Options